China Foreign Brand Boycott To Spill To Health Sector?
Cotton Row, China Risk and Ways Forward
Amid a rising tide of sentiment against foreign consumer brands in China, observers say the impact could be far-reaching. But other factors may be more important than public opinion, and innovation will remain a key to success for health sector players.
You may also be interested in...
While new legislation has pushed prescription drug pricing high up the political agenda for US lawmakers, the issue has also come into the spotlight again for Chinese regulators, which have just launched new investigations into two officials. While the two countries are taking drastically different routes to tackling pricing, the developments show compliance risks remain high in China.
The antibody-drug conjugate market is emerging as the next battleground for intense competition in China, with global partnerships becoming essential to win, as evidenced by a major new alliance between Innovent and Sanofi.
Where once there were promising prospects for cross-strait collaboration, biopharma firms in mainland China and Taiwan may now find themselves looking elsewhere for partners following a controversial visit to Taipei by US House Speaker Nancy Pelosi.